- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00333437
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is designed to evaluate the safety and efficacy of mycophenolate mofetil (CellCept) for the treatment of symptomatic pulmonary alveolitis due to systemic sclerosis (SSc). This study utilizes a prospective, open-label, experimental design.
Primary Hypothesis: The alveolitis in patients with SSc, as defined by decreased forced vital capacity (FVC), bronchoalveolar lavage (BAL), and High Resolution Chest Tomography (HRCT) is responsive to 1 year of daily mycophenolate mofetil therapy.
Secondary Hypothesis: Quality of life, six-minute walk and single-breath diffusing capacity for carbon monoxide (DLCO) improve in patients with SSc mediated alveolitis after therapy with mycophenolate mofetil. This response to therapy is associated with a change in the inflammatory cytokine profile present in BAL fluid.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- UCSF, 400 Parnassus Ave
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To participate in this study, patients must first undergo a BAL and HRCT. To be eligible to undergo HRCT and BAL (under the purview of this trial), prospective patients must meet the following criteria:
- Aged 21-70.
- Negative pregnancy test (with a sensitivity of at least 50 mIU/mL) for females of child-bearing potential
- All patients must fulfill the criteria for SSc by American College of Rheumatology (ACR) criteria (Subcommittee for Scleroderma Criteria 1980).
- FVC < 85% of predicted.
- SSc for no more than 7 years with onset defined as the date of the first non-Raynaud manifestation.
- Patients may have limited (cutaneous thickening distal but not proximal to elbows and knees, with or without facial involvement) or diffuse (cutaneous thickening proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc (Medsger 1995).
- Abnormal DLCO and abnormalities on the plain chest radiograph are not required, although a normal DLCO would be unusual in the face of significant ventilatory restriction due to SSc lung disease.
- To be eligible to take study medication, the patient must meet not only the criteria above, but also must have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils in screening BAL fluid and/or ground glass opacification on HRCT.
- Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 1 week before beginning therapy. CellCept therapy will not be initiated until a report of a negative pregnancy test has been obtained.
- Effective contraception must be used before beginning CellCept therapy, during therapy, and for 6 weeks following discontinuation of therapy, even where there has been a history of infertility, unless due to hysterectomy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy does occur during treatment, the physician and patient should discuss the desirability of continuing the pregnancy.
Exclusion Criteria:
- FVC < 45% of predicted or DLCO (corrected for hemoglobin [Hgb] but not for alveolar volume) < 35% of predicted (suggestive of severe, probably irreparable, disease).
- Leukopenia (white blood cell count < 4000) or thrombocytopenia (platelet count < 100,000).
- Serum creatinine ≥ 2.0 mg/dl.
- Pregnancy, breast feeding, unreliability, drug abuse, or chronic debilitating disease.
- Uncontrolled congestive heart failure.
- Active infection of the lung, or elsewhere, whose management would be compromised by mycophenolate mofetil.
- Prior treatment for alveolitis with mycophenolate mofetil or prior or current treatment for alveolitis with: D-penicillamine, methotrexate, colchicine, Potaba, or azathioprine.
- Other serious concomitant medical illness (e.g., cancer).
- Forced expiratory volume in 1 second (FEV1)/FVC ratio < 65%.
- If of childbearing potential, failure regularly to be employing two reliable means of contraception (i.e., condom, abstinence, intrauterine device (IUD), tubal ligation, vasectomy)
- Pulmonary hypertension (defined as an estimated systolic blood pressure (SBP) ≥ 35 mmHg measured by echocardiogram).
- Smoking of cigars, pipes, or cigarettes during the past 6 months.
- Clinically significant abnormalities on chest x-ray or HRCT scan other than interstitial lung disease (e.g., lung mass, evidence of active pulmonary infection).
- Use of prednisone (or equivalent) in doses > 10 mg per day.
- Does not have ≥ 3.0% neutrophils or ≥ 2.0% eosinophils on screening BAL fluid and does not have ground glass opacification on HRCT.
- Unable to take oral medication.
- Not able to comply with study procedures in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Mycophenolate Mofetil
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in Forced Vital Capacity (FVC)
Time Frame: Baseline, 12 months
|
compare pre- and post-therapy FVC (post- minus pre-).
Forced vital capacity (FVC) is the volume of air (liters) that can forcibly be blown out after full inspiration.
|
Baseline, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Bronchoalveolar Lavage (BAL) Components (Neutrophils, Eosinophils)
Time Frame: Baseline, 12 months
|
BAL samples were colleected from the affected lobe (as determined by lung CT scans) before beginning and after completing study therapy.
|
Baseline, 12 months
|
Change in Shortness of Breath (Self-reported)
Time Frame: Baseline, 12 months
|
Participants reported frequency of shortness of breath experienced with exertion
|
Baseline, 12 months
|
Mean Change in Six Minute Walk Distance
Time Frame: 12 months
|
Comparison of 6-minute walk distance before beginning and after completing study therapy
|
12 months
|
Mean Change in Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Time Frame: 12 months
|
DLCO was measured before beginning and after completion of study therapy
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jeffrey A Golden, MD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Connective Tissue Diseases
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Scleroderma, Localized
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Mycophenolic Acid
Other Study ID Numbers
- CEL371
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scleroderma, Systemic
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedSYSTEMIC SCLERODERMA | ALLOGENEIC MESENCHYMAL STEM CELLS | ADULTFrance
-
BiocadRecruitingSystemic SclerodermaRussian Federation
-
Rennes University HospitalCompleted
-
University Hospital, LilleRecruiting
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Boston UniversityRegeneron PharmaceuticalsCompletedSystemic Sclerosis | Scleroderma | Diffuse Systemic Sclerosis | Diffuse SclerodermaUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
University Hospital, Strasbourg, FranceRecruiting
-
University Hospital, LilleCompletedSystemic SclerodermaFrance
Clinical Trials on Mycophenolate mofetil
-
University of GiessenNovartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg UniversityCompletedPolyomavirus InfectionsGermany
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States
-
Nanjing University School of MedicineCompletedNephritis | Henoch-Schoenlein PurpuraChina
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...WithdrawnSteroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeChina
-
Nanjing University School of MedicineCompletedVasculitis | Anti-Neutrophil Cytoplasmic AntibodyChina
-
Teva Branded Pharmaceutical Products R&D, Inc.ParexelTerminatedStable Renal Transplant Recipients
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Fred Hutchinson Cancer CenterUniversity of WashingtonCompleted
-
Samsung Medical CenterUnknown